Arena Pharmaceuticals

We are a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors (GPCRs) to address unmet medical needs. Our internally discovered drug for chronic weight management, BELVIQ ® (lorcaserin HCl), was approved by the FDA for marketing in the United States to adults who are overweight with a comorbidity or obese, and was made available to patients by our collaborator, Eisai, by prescription in June 2013. In February 2015, BELVIQ was also approved for weight management in South Korea and will be marketed by our collaborator, Ildong.
Type
Public
HQ
San Diego, US
Founded
1977
Employees
228 (est)-29%
Arena Pharmaceuticals was founded in 1977 and is headquartered in San Diego, US

Arena Pharmaceuticals Locations

San Diego, US
Zofingen, CH

Arena Pharmaceuticals Metrics

Arena Pharmaceuticals Summary

Market capitalization

$333 M

Closing share price

$1.38
Arena Pharmaceuticals's current market capitalization is $333 M.

Arena Pharmaceuticals Financials

Arena Pharmaceuticals's revenue is $38.3 M in FY, 2015 which is 3.67% increase from the previous period.
FY, 2013FY, 2014FY, 2015

Revenue

$81.4 M$37 M$38.3 M

Gross profit

$77 M$30.6 M$29.7 M

Operating income

$-22.9 M$-105 M$-103 M

Operating expense total

$104 M$136 M$133 M

Net Income

$-19.4 M$-60.5 M$-108 M

Operating cash flow

$65.8 M$-58.7 M$-7.03 M

    Arena Pharmaceuticals Market Value History

    Arena Pharmaceuticals News

    Arena Pharmaceuticals Company Life

    You may also be interested in